Preclinical Pharmacology

WuXi Biology offers in integrated services with in vitro biology, DMPK and toxicology studies to provide datasets and evidence for IND-enabling.

Large and expanding infrastructure

AAALAC-accredited animal facility
IVC-cage capacity in SPF barrier

Growing number of available animal models

1700+ tumor models: 1400+ PDX / 300+ CDX / 80+ syngeneic models
Gene KO/KI animals

Exploration in new technologies including patient-derived organoids, single cell RNAseq, and NanoString

We offer Pharmacokinetic studies and ADME (stabilities, plasma protein binding, transporter, tissue distribution, metabolic ID, excretion), safety and efficacy studies with both in vitro and in vivo models.

Safety

In vitro assays
- Protein/enzyme activity, induction & inhibition
- Transferase assays
- Cellular toxicity with primary cell cultures
- ADC off-target screening
- Genetic toxicity
In vivo toxicity
- Toxicokinetics (TK)
- Systemic & specific tox
- Short & long term tox
- Clinical relevance (dose, dose escalation)
- Clinical safety

Efficacy

Benchmark, selection
- Animal efficacy test
- Animal models of clinical relevance
- Target engagement
- PD profiling
- Biomarkers
PK/PD study / PK parameters for efficacy
Mechanistic pharmacology
- Gene expression profiling (NanoString)
- ‘Omics’ studies
- Disease mechanism

PK / ADME

Benchmark, selection
PK
- Standard PK
- PK parameters for efficacy
- Dosing regimen design
ADME
- Stability testing
- Plasma protein binding
- Transporter studies
- Tissue distribution
- Metabolite ID
- Excretion analysis